Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Why Don't the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment. | Int J Mol Sci | 2023 | 36902456 | PubTator, text mining | PubMed |
| Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. | Int J Mol Sci | 2023 | 36902450 | PubTator, text mining | PubMed |
| The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms. | Int J Mol Sci | 2023 | 36902299 | PubTator, text mining | PubMed |
| The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. | Int J Mol Sci | 2023 | 36902139 | PubTator, text mining | PubMed |
| Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. | Cancers (Basel) | 2023 | 36900407 | PubTator, text mining | PubMed |
| The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. | Cancers (Basel) | 2023 | 36900380 | PubTator, text mining | PubMed |
| Emerging Therapies in CLL in the Era of Precision Medicine. | Cancers (Basel) | 2023 | 36900373 | PubTator, text mining | PubMed |
| The Heterogeneous Complexity of Myeloid Neoplasm: Multi-Level Approaches to Study the Disease. | Cancers (Basel) | 2023 | 36900241 | PubTator, text mining | PubMed |
| Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology. | Cancers (Basel) | 2023 | 36900239 | PubTator, text mining | PubMed |
| Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse? | Cancers (Basel) | 2023 | 36900222 | PubTator, text mining | PubMed |
| Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. | Cancers (Basel) | 2023 | 36900154 | PubTator, text mining | PubMed |
| Host Cell Restriction Factors Blocking Efficient Vector Transduction: Challenges in Lentiviral and Adeno-Associated Vector Based Gene Therapies. | Cells | 2023 | 36899868 | PubTator, text mining | PubMed |
| Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. | Transl Lung Cancer Res | 2023 | 36895930 | PubTator, text mining | PubMed |
| Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study. | J Hematol | 2023 | 36895293 | PubTator, text mining | PubMed |
| Transcription elongation defects link oncogenic splicing factor mutations to targetable alterations in chromatin landscape. | bioRxiv | 2023 | 36891287 | PubTator, text mining | PubMed |
| Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. | Cold Spring Harb Mol Case Stud | 2023 | 36889927 | PubTator, text mining | PubMed |
| Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. | Cell Rep Med | 2023 | 36889320 | PubTator, text mining | PubMed |
| SpliceTools, a suite of downstream RNA splicing analysis tools to investigate mechanisms and impact of alternative splicing. | Nucleic Acids Res | 2023 | 36864749 | PubTator, text mining | PubMed |
| Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. | JCO Precis Oncol | 2023 | 36862966 | PubTator, text mining | PubMed |
| Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. | Haematologica | 2023 | 36861402 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=29